>>14193724

Oxitec

https://www.oxitec.com/

"CEO Grey Frandsen was appointed in 2017. He is an American who led start-up initiatives in the U.S. government and the private and non-profit sectors on matters relating to national and global public health security, biotechnology and crisis response.[

Frandsen led the company's transition to its 2nd generation technology while expanding its programs to advance its mosquito and agricultural technologies.

Oxitec established partnerships with large agricultural industry leaders andthe Bill & Melinda Gates Foundation, which helped to advance Oxitec's 2nd generation technology.

Frandsen was named one of Malaria No More's 10-to-End innovators in 2019.Frandsen is the chairman of the board of directors forPilgrim Africa, an NGO implementing malaria control programs in Ugandafunded by the Bill & Melinda Gates Foundation, the Global Fund and private donors."

>>14193996

Grey Frandsen was appointed to the role of Oxitec’s CEO in 2017. During his tenure, the company has expanded its public health and agriculture technology pipeline, upgraded its gene technology platform, established new R&D collaborations, and strengthened core R&D and operational capacities globally. Since 2017 the company has also expanded strategic partnerships in agriculture, developed its first commercial solutions, seeded new country programs, and secured landmark regulatory approvals for the company’s first-in-class agricultural and public health technologies.

Recently named one of the ‘10 to End Malaria’ by Malaria No More, Grey has served in a range of leadership roles in the public and private sectors focused on advancing solutions to global challenges. Starting in 1999 as co-founder of his first technology start-up while at university, Grey has started or led early-stage companies in technology, biotechnology, and B2C. During public service, Grey’s roles included being the first chief of staff for the U.S. Secretary of State’s Office of Reconstruction and Stabilization, as well as other positions focused on national security priorities.

Grey has served asan advisor to the U.S. Centers for Disease Control, U.S. Agency for International Development (USAID), the U.S. Department of Defence, the University of California San Francisco’s (UCSF) Global Health Group, the Caribbean Public Health Agency, the U.S. Government’s Center for Disaster and Humanitarian Assistance Medicine, and other organizations.

Grey has also served as an adjunct faculty member at UCSF and the Uniformed Services University of Health Science. Since 2016, Grey has beenchair of the board of directors for Pilgrim Africa, an African NGO focused on malaria elimination and food securityfunded by the Bill & Melinda Gates Foundation, the Global Fund, USAID’s President’s Malaria Initiative, and the UK Government, which continues his 20+ years of work on the African continent.

Grey received a bachelor’s degree from the University of California Los Angeles, and a master’s degree at theJohns HopkinsUniversity School for Advanced International Studies in international economics and international affairs. Grey was a U.S. President’s Management Fellow, a Manfred Woerner Fellow with the German Marshall Fund, and a fellow at the International Crisis Group inBrussels and Nairobi.

Grey is a native of Seattle, WA, and lives in Virginia with his wife and four children.

>>14193996

>>14194014

>>14194031

>>14193996

>Oxitec

>https://www.oxitec.com/

Parent company: https://thirdsecurity.com/

peep incoming object

>>14194098

https://mologic.co.uk/about-us/our-team/

>>14194208

"Mologic to become a ‘Social Enterprise’ after acquisition by social impact funders and investors

Home/All News/Mologic to become a ‘Social Enterprise’ after acquisition by social impact funders and investors

Previous

Social Enterprise set up by group of philanthropic funds led by George Soros’ Economic Development Fund, with support from Bill & Melinda Gates Foundation

New venture aims to expand affordable access to medical technology in low- and middle-income countries

Mologic and sister company, Global Access Diagnostics (GAD) integrated under Global Access Health

New York, USA, and Bedford, UK, 19 July 2021: A group of philanthropic funds and investors led by the Soros Economic Development Fund (SEDF), with support from the Bill & Melinda Gates Foundation, is today announcing the launch of Global Access Health (GAH), a social enterprise that will seek to expand access to affordable state-of-the-art medical technology through decentralized research, development, and manufacturing in and for the Global South.

The group has financed the acquisition of Mologic Ltd, a world leading innovator in the development of lateral flow and rapid diagnostic technologies including tests that can help combat tropical diseases such as dengue, bilharzia, and river blindness, as well as for COVID-19.

The members of GAH will invest at least £30 million ($41 million) in this deal.

The transaction is important in that it transitions a world-class for-profit company into a social enterprise and allows it to entirely reinvest its profits in pursuing these goals. This transformation will give it the ability to address gaps in the provision of global diagnostics in low-income communities and regions that profit-focused business has failed to address.

SEDF is the impact investment arm of the Open Society Foundations. Sean Hinton, SEDF’s Chief Executive Officer, said: “The COVID-19 pandemic has painfully demonstrated the fundamental inequities in global public health, and in particular the crucial importance of access in low- and middle-income countries to low-price, high-quality life-saving diagnostic tools. In this unique transaction, philanthropic funds and investors are working together with a skilled and visionary management team in a truly innovative way to address at least one part of that failure by enabling a cutting edge commercial business to focus all its resources on solving one of the world’s most pressing public health issues.”

Mologic was established in 2003 by Mark Davis and his father Professor Paul Davis, one of the original creators of ClearBlue, the world’s first home pregnancy test. Mologic’s technology has broad application across markets and disease states where rapid, accurate point-of-need testing can help make a significant difference in patient care and patient outcomes. Its extensive work in developing affordable testing for neglected tropical diseases has been supported by grant funding from a range of donors, and most significantly by the Bill & Melinda Gates Foundation.

Mark Davis, CEO of Mologic, welcomed the conclusion of the deal: “Mologic’s transition into a social enterprise is a deliberate, logical and natural step for a company focused on delivering affordable diagnostics and biotechnology to places that have been left underserved by the relentless pursuit of profiteering. With the support of our shareholders, donors and partners we have come a long way; we believe we have the people and the skills required for the challenges and opportunities ahead. And we hope this unique transaction will be an example for others to follow.”

pt 1 of 2

>>14194215

“Testing, or diagnostics, are vital for every day public health needs, to enable doctors and medical professionals to provide patients with proper treatment as early as possible,” said Roxana Bonnell, a public health expert at the Open Society Foundations. “As we have seen during the COVID-19 pandemic, access to testing is absolutely essential when it comes to containing the spread of contagious disease—an issue that ultimately affects us all.”

As part of the transaction GAH will integrate both Mologic and a sister non-profit entity, Global Access Diagnostics (GAD), which was established by the founders of Mologic with support from SEDF, the UK’s DFID and others in April 2020. GAD is focused on low-cost manufacturing of diagnostic tests, and licenses Mologic’s technology in Africa and South Asia. Mark Davis will continue to serve as CEO of Mologic, with Paul Davis continuing as Chief Scientific Officer. GAD will continue as a separate non-profit entity, under CEO Mark Radford. Both will be wholly-owned and governed by GAH. A number of other philanthropic funds and investors are currently engaged in finalizing their participation in GAH to further the scope and ambition of the organisation.

The transaction involves the acquisition by the investing consortium of all Mologic’s existing shares, including those held by two private investment managers, Foresight Group LLP, and Calculus Capital.

SEDF’s investments in GAH and GAD are part of a portfolio of recent investments made in service of Open Society Foundations’ commitment to expand global access to affordable, quality public health products and technologies. These investments build on two decades of foundation support for improved access to medicines advocacy and policy making globally.

The Open Society Foundations, founded by its chairman George Soros, is the world’s largest private funders of human rights and social justice advocacy groups. The Soros Economic Development Fund, established in 1997, pursues impact investments that are aligned with Open Society’s broader mission, and currently holds 35 investments totaling c.$300m."

pt 2 of 2